https://www.selleckchem.com/
selectivity and consistency of the observed effects. We also show that analgesia persists after congruent SCS-VR had stopped, indicating carry over effects and underlining its therapeutic potential. Linking latest VR technology with recent insights from the neuroscience of body perception and SCS neuromodulation, our personalized new SCS-VR platform highlights the impact of immersive digiceutical therapies for chronic pain.Registration clinicaltrials.gov, Identifier NCT02970006. Long-term follow-up of patients treated with open-label placebo (OLP) are nonex
Like
Comment
Share
